Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06412562 in advanced Parkinson's disease
NCT03665454Phase 1Completed
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Sep 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing PF-06412562 with Standard of Care (2 arms). Primary endpoint: Safety and tolerability of PF-06412562 assessed by blood sample results at Day 4. Started Sep 2018; status: completed.
02
Drugs
razpipadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03665454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665454.